REFERENCES
1.
Bhatt
DL, Steg
PG, Miller
M, Brinton
EA, Jacobson
TA, Ketchum
SB, Doyle
RT
Jr., Juliano
RA, Jiao
L, Granowitz
C, Tardif
JC, Ballantyne
CM. Cardiovascular Risk Reduction with Icosapent Ethyl for
Hypertriglyceridemia. N Engl J Med. 2019; 380 (1):
11–22. https://doi.org/10.1056/NEJMoa1812792.
2. Arai H, Ishibashi S, Bujo H, Hayashi T, Yokoyama S, Oikawa S,
Kobayashi J, Shirai K, Ota T, Yamashita S, Gotoda T, Harada-Shiba M,
Sone H, Eto M, Suzuki H, Yamada N. Management of type IIb dyslipidemia.J Atheroscler Thromb. 2012; 19 (2): 105–114.
https://doi.org/10.5551/jat.10447.
3. Schaefer JR. Unraveling hyperlipidemia type III
(dysbetalipoproteinemia), slowly. Eur J Hum Genet. 2009;17 (5): 541–542. https://doi.org/10.1038/ejhg.2008.222.
4. Maharaj S, Chang S, Nayak SB. Familial hypercholesterolemia
presenting with multiple nodules of the hands and elbow. Clin Case
Rep. 2015; 3 (6): 411–414.
https://doi.org/10.1002/ccr3.249.
5. Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M,
Dobashi K, Nohara A, Bujo H, Miyauchi K, Yamashita S, Yokote K.
Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia
2017. J Atheroscler Thromb. 2018; 25 (8): 751–770.
https://doi.org/10.5551/jat.CR003.
6. Roga G, Jithendriya M. Eruptive xanthoma: Warning sign of systemic
disease. Cleve Clin J Med. 2016; 83 (10): 715–716.
https://doi.org/10.3949/ccjm.83a.15126.
7. Solak B, Kara RO, Acikgoz SB, Kosem M. First and only symptom of
undiagnosed diabetes mellitus: eruptive xanthoma. BMJ Case Rep.2015; 2015 : bcr2015212160.
https://doi.org/10.1136/bcr-2015-212160.
8. Tsuchiya S, Sawada S, Takeda K, Takahashi K, Nakajima T, Kohata M,
Kurosawa S, Satake C, Imai J, Kikuchi K, Aiba S, Katagiri H. Eruptive
xanthomas in a patient with soft-drink diabetic ketosis and
apolipoprotein E4/2. Endocr J. 2019; 66 (1): 107–114.
https://doi.org/10.1507/endocrj.EJ18-0356.
9. Kashif M, Kumar H, Khaja M. An unusual presentation of eruptive
xanthoma: A case report and literature review. Medicine
(Baltimore). 2016; 95 (37): e4866.
https://doi.org/10.1097/MD.0000000000004866.
10. Abdelghany M, Massoud S. Eruptive xanthoma. Cleve Clin J Med.2015; 82 (4): 209–210.
https://doi.org/10.3949/ccjm.82a.14081.
11. Zaremba J, Zaczkiewicz A, Placek W. Eruptive xanthomas.Postepy Dermatol Alergol. 2013; 30 (6): 399–402.
https://doi.org/10.5114/pdia.2013.39439.
12. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and
pathophysiological relations. Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub. 2014; 158 (2): 181–188.
https://doi.org/10.5507/bp.2014.016.
13. Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA.
Incidence of pancreatitis, secondary causes, and treatment of patients
referred to a specialty lipid clinic with severe hypertriglyceridemia: a
retrospective cohort study. Lipids Health Dis. 2011; 10 :
157. https://doi.org/10.1186/1476-511X-10-157.
14. Boullart ACI, de Graaf J, Stalenhoef AF. Serum triglycerides and
risk of cardiovascular disease. Biochim Biophys Acta. 2012;1821 (5): 867–875.
https://doi.org/10.1016/j.bbalip.2011.10.002.
15. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common
threads and missing links. Cell. 2012; 148(5): 852–871.
https://doi.org/10.1016/j.cell.2012.02.017.
16. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in
healthy longevity and obesity-related diseases. Cell Metab. 2013;17 (2): 185–196. https://doi.org/10.1016/j.cmet.2013.01.001.
17. Zhou Y, Rui L. Leptin signaling and leptin resistance. Front
Med. 2013; 7 (2): 207–222.
https://doi.org/10.1007/s11684-013-0263-5.
18. Grant RW, Dixit VD. Adipose tissue as an immunological organ.Obesity (Silver Spring). 2015; 23 (3): 512–518.
https://doi.org/10.1002/oby.21003.
19. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory
basis of metabolic disease. Cell. 2010; 140 (6):
900–917. https://doi.org/10.1016/j.cell.2010.02.034.
20. Teo CF, Wollaston-Hayden EE, Wells L. Hexosamine flux, the O-GlcNAc
modification, and the development of insulin resistance in adipocytes.Mol Cell Endocrinol. 2010; 318 (1-2): 44–53.
http://doi.org/10.1016/j.mce.2009.09.022.
21. Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH,
Cohen JC. Rare loss-of-function mutations in ANGPTL family members
contribute to plasma triglyceride levels in humans. J Clin
Invest. 2009; 119 (1): 70–79.
https://doi.org/10.1172/JCI37118.
22. Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H,
Oka Y, Katayama S. ANGPTL3 is increased in both insulin-deficient and
-resistant diabetic states. Biochem Biophys Res Commun. 2004;317 (4): 1075–1079.
https://doi.org/10.1016/j.bbrc.2004.03.151.
23. Shimamura M, Matsuda M, Kobayashi S, Ando Y, Ono M, Koishi R,
Furukawa H, Makishima M, Shimomura I. Angiopoietin-like protein 3, a
hepatic secretory factor, activates lipolysis in adipocytes.Biochem Biophys Res Commun. 2003; 301 (2): 604–609.
https://doi.org/10.1016/s0006-291x(02)03058-9.
24. Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-Like
Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.Int J Mol Sci. 2021; 22 (14): 7310.
https://doi.org/10.3390/ijms22147310.
25. Toth PP. Triglyceride-rich lipoproteins as a causal factor for
cardiovascular disease. Vasc Health Risk Manag. 2016;12 : 171–183. https://doi.org/10.2147/VHRM.S104369.
26. Lusis AJ. Atherosclerosis. Nature. 2000. 14; 407(6801):
233–241. https://doi.org/10.1038/35025203.
27. Parhofer KG, Laufs U. The Diagnosis and Treatment of
Hypertriglyceridemia. Dtsch Arztebl Int. 2019; 116 (49):
825–832. https://doi.org/10.3238/arztebl.2019.0825.
28.
Iso
H, Naito
Y, Sato
S, Kitamura
A, Okamura
T, Sankai
T, Shimamoto
T, Iida
M, Komachi
Y. Serum triglycerides and risk of coronary heart disease among Japanese
men and women. Am J Epidemiol. 2001; 153 (5): 490–499.
https://doi.org/10.1093/aje/153.5.490.
29. Marston NA, Giugliano RP, Im K, Silverman MG, O’Donoghue ML, Wiviott
SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering
and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering
Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of
Randomized Controlled Trials. Circulation. 2019;140 (16): 1308–1317.
https://doi.org/10.1161/CIRCULATIONAHA.119.041998.
30. Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant
Lipoproteins. J Atheroscler Thromb. 2017; 24 (2):
95–109. https://doi.org/10.5551/jat.RV16003.
31. Alipour A, Valdivielso P, Elte JWF, Janssen HW, Rioja J, van der
Meulen N, Mechelen R, Njo TL, González-Santos P, Rietveld AP, Cabezas
MC. Exploring the value of apoB48 as a marker for atherosclerosis in
clinical practice. Eur J Clin Invest. 2012; 42 (7):
702–708. https://doi.org/10.1111/j.1365-2362.2011.02635.x.
32. Masuda D, Sugimoto T, Tsujii K, Inagaki M, Nakatani K, Yuasa-Kawase
M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Kawamoto T,
Matsuyama A, Sakai N, Komuro I, Yamashita S. Correlation of fasting
serum apolipoprotein B-48 with coronary artery disease prevalence.Eur J Clin Invest. 2012; 42 (9): 992–999.
https://doi.org/10.1111/j.1365-2362.2012.02687.x.